<DOC>
	<DOCNO>NCT01912456</DOCNO>
	<brief_summary>The aim study assess efficacy C1-esterase inhibitor prevent hereditary angioedema attack administer skin subject hereditary angioedema . The safety C1-esterase inhibitor also assess . Each subject enter run-in period 8-weeks . Subjects complete run-in period eligible enter treatment phase comprise two sequential treatment period . In treatment phase , subject randomize one four arm consist treatment low- higher-volume C1-esterase inhibitor one treatment period treatment low- higher-volume placebo treatment period . The study measure number hereditary angioedema attack subject experience receive treatment .</brief_summary>
	<brief_title>A Study Evaluate Clinical Efficacy Safety Subcutaneously Administered C1-esterase Inhibitor Prevention Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Hereditary Angioedema Types I II</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>RunIn Period Males female age 12 year old . A clinical diagnosis hereditary angioedema type I II . Hereditary angioedema attack consecutive 2month period require acute treatment , medical attention , cause significant functional impairment . For subject use oral therapy prophylaxis HAE attack within 3 month Screening : use stable regimen within 3 month Screening , plan change . Eligibility Criteria Entering Treatment Period 1 : Laboratory confirmation type I type II hereditary angioedema , include C1esterase inhibitor functional activity le 50 % AND C4 antigen level laboratory reference range . No clinically significant abnormality assess use laboratory parameter . During participation runin period , subject must experience hereditary angioedema attack require acute treatment , require medical attention , cause significant functional impairment . RunIn Period History clinical significant arterial venous thrombosis , current history clinically significant prothrombotic risk . Incurable malignancy screen . Any clinical condition interfere evaluation C1esterase inhibitor therapy . Clinically significant history poor response C1esterase therapy management hereditary angioedema . Receiving therapy prohibit protocol , include medication hereditary angioedema prophylaxis . Female subject start take change dose hormonal contraceptive regimen hormone replacement therapy ( i.e. , estrogen/progesteronecontaining product ) within 3 month prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hereditary Angioedema</keyword>
</DOC>